Skip to main content

Table 4 Correlation of KRAS mutations with clinicopathological features of CRC patients

From: The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order

Variables

Number (%)

KRAS

Univariate

Multivariate

Mutant (%)

Wild-type (%)

Odds ratio (95 % CI)

p value

Odds ratio (95 % CI)

p value

Gender

Male

657 (59.78)

233 (35.46)

424 (64.54)

Ref.

 

Ref.

 

Female

442 (40.22)

204 (46.15)

238 (53.85)

1.56 (1.22–1.99)

<0.001

1.64 (1.26–2.12)

<0.001

Age (years)

≤50

232 (21.11)

41 (17.67)

191 (82.33)

Ref.

 

Ref.

 

>50

867 (78.89)

396 (45.67)

471 (54.33)

3.92 (2.72–5.63)

<0.001

4.17 (2.85–6.10)

<0.001

Sub-localization

Rectum

371 (33.76)

139 (37.47)

232 (62.53)

Ref.

 

Ref.

 

Prioximal colon

373 (33.94)

155 (41.55)

218 (58.45)

1.19 (0.88–1.59)

0.254

0.85 (0.62–1.17)

0.333

Distal colon

355 (32.30)

143 (40.28)

212 (59.72)

1.13 (0.84–1.52)

0.437

0.95 (0.69–1.31)

0.754

Dukes’ stage

A + B

614 (56.23)

244 (39.74)

370 (60.26)

Ref.

 

Ref.

 

C + D

478 (43.77)

192 (40.17)

286 (59.83)

1.02 (0.80–1.30)

0.886

0.99 (0.77–1.29)

0.963

Pathology

Non-ADC

54 (4.91)

10 (18.52)

44 (81.48)

Ref.

 

Ref.

 

ADC

1045 (95.09)

427 (40.86)

618 (59.14)

3.04 (1.51–6.11)

0.002

2.41 (1.12–5.17)

0.024

Differentiation

Well

78 (7.10)

23 (29.49)

55 (70.51)

Ref.

 

Ref.

 

Moderate

752 (68.43)

310 (41.22)

442 (58.78)

1.68 (1.01–2.79)

0.046

1.10 (0.62–1.96)

0.742

Poor

256 (23.29)

101 (39.45)

155 (60.55)

1.56 (0.90–2.69)

0.112

1.24 (0.66–2.30)

0.503

Unknown

13 (1.18)

3 (23.08)

10 (76.92)

0.72 (0.18–2.85)

0.637

0.53 (0.13–2.24)

0.388

  1. KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, CRC colorectal cancer, CI confidence interval, ADC adenocarcinoma, Ref. reference group